|

Mesna Clinical Trials

17 actively recruiting trials across 9 locations

Also known as: 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate +14 more

Pipeline

Early 1: 1Phase 1: 9Phase 2: 3Phase 1/2: 3

Top Sponsors

  • St. Jude Children's Research Hospital8
  • National Cancer Institute (NCI)2
  • University of Rochester1
  • M.D. Anderson Cancer Center1
  • Indapta Therapeutics, INC.1

Indications

  • Cancer17
  • Hematologic Malignancy3
  • Lymphoma3
  • Neuroblastoma2
  • Acute Lymphoblastic Leukemia2

Memphis, Tennessee8 trials

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

St. Jude Children's Research Hospital

Phase 1
CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

St. Jude Children's Research Hospital

Phase 2
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

St. Jude Children's Research Hospital

Phase 1
CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

St Jude Children's Research Hospital

Phase 1
CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

St. Jude Children's Research Hospital

Phase 1
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

St. Jude Children's Research Hospital

Phase 1
Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia

St. Jude Children's Research Hospital

Phase 1
TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies

St. Jude Children's Research Hospital

Phase 1

Other1 trial

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Early 1

Birmingham, Alabama1 trial

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Children's Hospital of Alabama

Phase 2

Duarte, California1 trial

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

City of Hope

Phase 1/2

Los Angeles, California1 trial

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Valkyrie Clinical Trials

Phase 1/2

Sacramento, California1 trial

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

University of California, Davis Comprehensive Cancer Center

Phase 1

Bethesda, Maryland1 trial

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

National Institutes of Health Clinical Center

Phase 1/2

Boston, Massachusetts1 trial

IS-free Treg HaploHCT

Dana Farber Cancer Institute

Phase 1

Rochester, New York1 trial

Umbilical Cord Blood Transplantation From Unrelated Donors

Wilmot Cancer Institute

Houston, Texas1 trial

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.